NCT06685068 2026-04-14
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
Clinical Trials
39 trialsNCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05638334 2026-02-17
Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours
Servier
Phase 1 Terminated
NCT05756907 2026-02-03
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Sonnet BioTherapeutics
Phase 1/2 Terminated
NCT06334783 2026-01-21
TIL for Patients With Advanced Solid Tumor
Hervor Therapeutics
Phase 1 Terminated
NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT06509906 2025-12-18
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
Phase 1 Terminated
NCT05147350 2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1 Terminated
NCT06232408 2025-11-21
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
Repare Therapeutics
Phase 1 Terminated
NCT06289894 2025-11-21
A Study of BRY805 in Participants With Advanced Solid Tumors
BioRay Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT05821777 2025-09-25
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
Centessa Pharmaceuticals plc
Phase 1/2 Terminated
NCT06182579 2025-09-17
Phase I Study of RiMO-401 With Radiation in Advanced Tumors
Coordination Pharmaceuticals, Inc.
Phase 1 Terminated
NCT06226766 2025-09-10
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2 Terminated
NCT05208177 2025-08-22
A Study of SHR-1802 in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT06074705 2025-08-22
A Study of DS-1471a In Subjects With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Terminated
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT04259450 2025-07-17
Study to Assess AFM24 in Advanced Solid Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT05580770 2025-02-17
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT05382936 2025-01-09
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Stemline Therapeutics, Inc.
Phase 1 Terminated
NCT04488003 2024-06-04
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
BioMed Valley Discoveries, Inc
Phase 2 Terminated
NCT05309512 2024-05-01
Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Terminated
NCT05148533 2024-04-15
A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Terminated
NCT04761601 2024-03-13
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
1200 Pharma, LLC
Phase 1 Terminated
NCT05148195 2024-03-13
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT04430348 2024-03-12
PTX-35 in Patients With Advanced Solid Tumors
Heat Biologics
Phase 1 Terminated
NCT04513067 2023-12-08
A Safety Study of YQ23 in Advanced Solid Tumors Patients
New Beta Innovation Limited
Phase 1 Terminated
NCT05255484 2023-10-25
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Terminated
NCT05073484 2023-10-11
Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients
Bio-Thera Solutions
Phase 1 Terminated
NCT04865159 2023-09-21
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
Kura Oncology, Inc.
Phase 1 Terminated
NCT04471415 2023-06-12
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Dracen Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT03871855 2023-06-05
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
NCT04381325 2023-04-05
A Study of MSB0254 Injection in Advanced Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1 Terminated
NCT05008445 2023-03-09
Study of LM-102 in Patients With Advance Solid Tumors
LaNova Medicines Limited
Phase 1/2 Terminated
NCT04557384 2023-02-27
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT04162301 2021-04-15
A Study of CS3002 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Terminated
NCT02553499 2019-11-04
MK-1248-001
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02979392 2019-09-25
Phase I Study of TENPA in Advanced Solid Cancer
Seoul National University Hospital
Phase 1 Terminated
NCT01453387 2017-05-08
MSC2015103B in Solid Tumors
EMD Serono
Phase 1 Terminated